PTCE - Medications - Section 1.2

Recognise and manage therapeutic duplications in medication regimens.

Recognise therapeutic duplication as the concurrent use of two or more drugs from the same class that provides no additive benefit to the patient. Identify overlapping regimens during drug regimen review and understand when a pharmacist intervention is required to resolve the duplication.

Therapeutic duplicationDrug regimen reviewPharmacist intervention

Practice question for this objective

Free sampleMedicationsmedium

During a drug regimen review, a technician notices that a patient, Tomasz Bellaire, is receiving both lisinopril 20 mg daily and ramipril 5 mg daily from two different prescribers. Both medicines belong to the same therapeutic class. What is the technician's most appropriate first action?

  • ADispense both medicines as written, because each was ordered by a separate prescriber with independent authority
  • BAlert the pharmacist to the duplicate ACE inhibitor therapy so the issue can be assessed and the prescribers contacted Correct
  • CSubstitute one of the two medicines for an angiotensin receptor blocker without contacting either prescriber
  • DReduce the lisinopril dose by half and dispense the ramipril at the full ordered strength
When a regimen review reveals two drugs of the same therapeutic class, the technician flags the duplication and escalates to the pharmacist rather than acting independently. Lisinopril and ramipril are both ACE inhibitors, so concurrent use is a therapeutic duplication that can cause additive hypotension and hyperkalaemia; resolving it requires pharmacist clinical judgement and prescriber contact, which sits beyond the technician's authority.

Why A is wrong: It is tempting because two valid prescriptions exist from two prescribers, but separate authority does not resolve the duplication of two ACE inhibitors, which raises the risk of hypotension and hyperkalaemia and must be flagged before dispensing.

Why B is correct: Lisinopril and ramipril are both ACE inhibitors, so taking both is a therapeutic duplication; the technician's role is to detect the flag and escalate to the pharmacist, who clinically evaluates and intervenes with the prescribers.

Why C is wrong: It seems reasonable because an ARB avoids stacking two ACE inhibitors, but a technician cannot change therapy on their own authority, and switching classes still requires a prescriber decision.

Why D is wrong: It appears to lower the combined effect, but altering a prescribed dose is outside the technician's scope and dose reduction does not address that two same-class agents are still being taken together.

See more PTCE practice questions, answers explained.

More in this domain

Back to all Medications objectives, or the PTCE cert hub.

Examworthy is not affiliated with or endorsed by PTCB. Original, blueprint-aligned practice material only.